Quarterly report [Sections 13 or 15(d)]

Stockholders’ Equity

v3.26.3
Stockholders’ Equity
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Stockholders’ Equity

Note 9 – Stockholders’ Equity

 

As of September 30, 2026, in accordance with the Certificate of Incorporation, the Company is authorized to issue 500,000,000 shares of common stock and 10,000,000 shares of preferred stock, each share having a par value of $0.0001.

 

Reverse Stock Split

 

On September 28, 2026, the Company effected a 1-for-15 reverse stock split of its issued and outstanding common stock. The Company’s common stock began trading on a split adjusted basis on September 28, 2026. No fractional shares were issued as a result of the 2026 Reverse Stock Split as stockholders otherwise entitled to a fractional share of common stock received a proportional cash payment. The 2026 Reverse Stock Split did not change the par value of the common stock or the authorized number of shares of common stock.

 

The 2026 Reverse Stock Split also affected the Company’s outstanding stock-based awards, warrants, and other exercisable or convertible securities and resulted in the shares of common stock underlying such instruments being reduced and the exercise price or conversion price being increased proportionally by the 2026 Reverse Stock Split ratio. Unless otherwise noted in these condensed consolidated financial statements, all shares of common stock, warrants convertible into shares of common stock, stock options, per share information, and related parameters specified in this quarterly report have been retroactively adjusted to reflect the 2026 Reverse Stock Split for all periods presented.

 

Common Stock

 

At-The-Market Equity Offering

 

On July 2, 2020, the Company entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”), pursuant to which the Company may offer and sell, from time to time, through BTIG, as sales agent and/or principal, shares of its common stock having an aggregate offering price of up to $50,000, subject to certain limitations on the amount of common stock that may be offered and sold by the Company set forth in the Sales Agreement. BTIG will be paid a 3% commission on the gross proceeds from each sale. The Company may terminate the Sales Agreement at any time; BTIG may terminate the Sales Agreement in certain limited circumstances. The Company did not sell any shares under the Sales Agreement during the nine months ended September 30, 2026 and 2025.

 

On July 23, 2026, pursuant to and in accordance with Section 12(a) of the Sales Agreement, BTIG notified the Company that BTIG is terminating the Sales Agreement effective immediately. The Company is not subject to any termination penalties or other expenses related to the termination of the Sales Agreement.

 

 

Preferred Stock

 

On February 13, 2025, the Company entered into a Securities Purchase Agreement (the “February 2025 Agreement”) with certain investors pursuant to which the Company sold, in a private placement (the “Offering”), an aggregate of 3,300 shares of the Company’s Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock”), initially convertible into up to 375,427 shares of the Company’s common stock with a stated value of $1,000 per share (the “Stated Value”), and warrants (the “2025 Warrants”) to purchase up to an aggregate of 200% of the shares of common stock into which the shares of Series C Preferred Stock are initially convertible, or 750,854 shares of common stock, for an offering price of $1,000 per share of Series C Preferred Stock and accompanying 2025 Warrants in two equal tranches, the second of which closed on April 8, 2025.

 

Pursuant to the February 2025 Agreement, on February 13, 2025, the Company issued and sold in an initial closing of the Offering (the “Initial Closing”), 1,650 shares of Series C Preferred Stock, initially convertible into up to 187,714 shares of common stock, and accompanying 2025 Warrants, initially exercisable for up to 375,427 shares of common stock, for gross proceeds to the Company of $1.65 million. On April 4, 2025, the Company obtained stockholder approval (“Stockholder Approval”) for the issuance of the Series C Preferred Stock and 2025 Warrants, as required by the rules and regulations of NYSE American LLC (the “NYSE American”), including Section 713 of the NYSE American Company Guide, and issued and sold, in a second closing of the Offering (the “Second Closing”), an additional 1,650 shares of Series C Preferred Stock, initially convertible into up to 187,714 shares of common stock, and accompanying 2025 Warrants, initially exercisable for up to 375,427 shares of common stock, for gross proceeds to the Company of $1.65 million.

 

On July 10, 2026, the Company entered into a Securities Purchase Agreement (the “Series D Purchase Agreement”) with certain investors, pursuant to which the Company agreed to issue and sell, in a private placement (the “Series D Financing”), an aggregate of 575 shares of the Company’s Series D Convertible Preferred Stock, par value $0.0001 per share (the “Series D Preferred Stock”), initially convertible into up to 109,524 shares of the common stock, with a stated value of $1,000 per share, together with warrants (the “Series D Warrants”) to purchase up to an aggregate of 100% of the shares of common stock into which the shares of Series D Preferred Stock are initially convertible, or 109,524 shares of common stock, for aggregate gross proceeds of up to $575, at an offering price of $1,000 per share of Series D Preferred Stock and accompanying Series D Warrant. The Series D Financing closed on July 10, 2026 and the Company received net proceeds of $510 therefrom.

 

The Company is required to obtain stockholder approval (the “2026 Stockholder Approval”) for the issuance of the shares of common stock issuable upon conversion of the Series D Preferred Stock and upon exercise of the Series D Warrants, the New Warrants and the Solicitation Agent Warrants (each as defined below), as may be required by the applicable rules and regulations of the NYSE American, including Section 713 of the NYSE American Company Guide. The Series D Preferred Stock will be convertible, at the option of the holder, at a conversion price of $5.25 per share, and the Series D Warrants will be exercisable at an exercise price of $5.25 per share and will expire five years, in each case from and after the date 2026 Stockholder Approval is received, subject to adjustment as provided in the applicable instruments.

 

As a result of the Series D Financing, the conversion price of the Series C Preferred Stock issued on February 13, 2025 and April 8, 2025 was adjusted from $8.79 to $5.25 pursuant to its stockholder-approved anti-dilution provisions. In accordance with ASC 260, Earnings Per Share (“ASC 260”), the Company recognized a deemed dividend of $2,372 attributable to the incremental value conveyed to the Series C Preferred Stockholders as a result of the adjustment. The deemed dividend was reflected as a reduction of income available to common stockholders in computing basic and diluted net loss per share, with an offsetting adjustment within stockholders’ equity.

 

 

The Series C Preferred shares were valued on the date of adjustment using the Option Pricing Model back-solve framework with the following assumptions:

 

Schedule of Date of Adjustment Using the Option Pricing Model

   

Pre-Adjustment

Assumptions

 
Expected volatility     140.05 %
Risk-free interest rate     4.18 %
Operating equity value on a consolidated basis   $ 16.3 million  
Exercise price on an equity value basis    

Respective Breakpoint value ranging from

$3.2 million to

$2.9 billion

 
Dividend yield     - %
Expected term     3.0  

 

   

Post-Adjustment

Assumptions

 
Expected volatility     140.05 %
Risk-free interest rate     4.18 %
Operating equity value on a consolidated basis     $20.1 million  
Exercise price on an equity value basis    

Respective Breakpoint value ranging from

$3.2 million to

$2.9 billion

 
Dividend yield     - %
Expected term     3.0  

 

Warrants

 

Series D Warrants:

 

The Series D Financing included the issuance of Series D Warrants to purchase up to 109,524 shares of common stock, as described above under “Preferred Stock”. The Series D Warrants have an exercise price of $5.25 per share, will become exercisable on the date 2026 Stockholder Approval is received (or such date that 2026 Stockholder Approval is no longer required under the rules of the applicable trading market) and will expire on the fifth anniversary of such date. As of September 30, 2026, Stockholder Approval had not been obtained and the Series D Warrants were not exercisable.

 

The following table summarizes the weighted-average assumptions, reflecting the value of the accompanying Series D Warrants as of July 10, 2026, used in calculating the Black Scholes fair value of the accompanying Series D warrants issued during the three and nine months ended September 30, 2026:

 

Schedule of Weighted-Average Assumptions in Black Scholes Fair Value

    Assumptions  
Expected volatility     46.00 %
Risk-free interest     4.25 %
Stock price (pre-stock split)   $ 0.76  
Exercise price (pre-stock split)   $ 0.35  
Dividend yield     — %
Expected term (in years)   5.4  

 

Series C Warrants:

 

As a result of the Series D Financing, the exercise price of the equity-classified 2025 Warrants was adjusted from $9.60 to $5.25. In accordance with ASC 260, the Company recognized a deemed dividend of $1,208, measured as the increase in the fair value of the 2025 Warrants immediately before and after the exercise-price adjustment. The deemed dividend was reflected as a reduction of income available to common stockholders in computing basic and diluted net loss per share, with an offsetting adjustment within stockholders’ equity.

 

The 2025 Warrants to purchase shares of common stock were valued on the date of modification using the Monte Carlo Simulation model with the following assumptions based on the valuation performed as of July 10, 2026:

 

Schedule of Weighted-Average Assumptions in Black Scholes Fair Value

   

Pre-Adjustment

Assumptions
 
Expected volatility     74.00 %
Risk-free interest rate     4.25 %
Stock price (pre-stock split)   $ 0.76  
Exercise price (pre-stock split)   $ 0.64  
Dividend yield     - %
Expected term (in years)     3.70  

 

    Post Adjustment Assumptions  
Expected volatility     74.00 %
Risk-free interest rate     4.25 %
Stock price (pre-stock split)   $ 0.76  
Exercise price (pre-stock split)   $ 0.35  
Dividend yield     - %
Expected term (in years)     3.70  

 

As of September 30, 2026, the Company had total outstanding warrants to purchase 835,584 shares of common stock, 13,334 shares at an exercise price of $262.50 per share (the “2024 Warrants”) and the 2025 and 2026 Warrants consisting of 822,250 shares at an exercise price of $5.25.

 

The 2024 Warrants were exercisable beginning October 2, 2024, and expire on the five-and-one-half year anniversary of the date of issuance, or October 5, 2029.

 

 

The 2025 Warrants purchased in the Initial Closing became exercisable on April 4, 2025, the effective date of the Stockholder Approval and will expire five years from the effective date of the Stockholder Approval, or April 4, 2030. The 2025 Warrants purchased in the Second Closing were immediately exercisable and will expire on April 8, 2030. The 2025 Warrants contain a call provision pursuant to which, if the trailing five-day VWAP of the common stock is 300% higher than (i.e., 400% of) the initial exercise price, the Company may, by delivering a call notice within ten trading days thereafter, require the holders to exercise all or a portion of the unexercised 2025 Warrants within 30 trading days after receipt of the call notice, after which any portion of the called 2025 Warrants not exercised will be cancelled. The 2025 Warrants also contain anti-dilution provisions pursuant to which the exercise price is subject to reduction upon certain dilutive issuances of common stock or common stock equivalents at a price below the then-current exercise price.

 

On August 15, 2025, the Company entered into Warrant Exchange Agreements (the “Exchange Agreements”) with certain holders (the “Exchanging Holders”) of 2024 Warrants to purchase an aggregate of 31,112 shares of common stock. Pursuant to the Exchange Agreements, on August 15, 2025, the Company issued to the Exchanging Holders one share of common stock for each Warrant, for an aggregate of 31,111 shares of common stock (the “Exchange Shares”), in exchange for the 2024 Warrants (the “Exchange”), in reliance on an exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”). Following the consummation of the Exchange, the 2024 Warrants held by the Exchanging Holders were cancelled.

 

Inducement Warrants:

 

On July 10, 2026, the Company entered into inducement offer letter agreements (the “Inducement Letters”) with certain holders (the “Warrant Holders”) of 2025 Warrants to purchase up to an aggregate of 499,107 shares of common stock.

 

Pursuant to the Inducement Letters, the Warrant Holders agreed to exercise for cash all or a portion of their 2025 Warrants at the current exercise price of $5.25 per share in consideration for the Company’s agreement to issue, in a private placement, new unregistered common stock purchase warrants (the “New Warrants”) to purchase up to 499,107 shares of common stock (100% of the number of shares of common stock issued pursuant to each such exercise of 2025 Warrants) (such transaction, the “Warrant Inducement”). The Warrant Inducement closed on July 10, 2026. The Company received net proceeds of $2,283 from the Warrant Inducement.

 

The New Warrants have an exercise price of $5.25 per share, will become exercisable on the date 2026 Stockholder Approval is received and will expire on the fifth anniversary of such date. As of September 30, 2026, 2026 Stockholder Approval had not been obtained and the New Warrants were not exercisable. The New Warrants contain a call provision pursuant to which, if the trailing five-day VWAP of the common stock is 300% higher than (i.e., 400% of) the initial exercise price, the Company may, by delivering a call notice within ten trading days thereafter, require the holders to exercise all or a portion of the unexercised New Warrants within 30 trading days after receipt of the call notice, after which any portion of the called New Warrants not exercised will be cancelled. The New Warrants also contain anti-dilution provisions pursuant to which the exercise price is subject to reduction upon certain dilutive issuances of common stock or common stock equivalents at a price below the then-current exercise price, subject to a floor price of $1.05 per share.

 

In connection with the Warrant Inducement, the Company issued the New Warrants as consideration to induce the Warrant Holders to exercise their outstanding 2025 Warrants. The fair value of the New Warrants issued as an inducement, totaling $3,541, was recognized as a deemed dividend to the exercising Warrant Holders. The deemed dividend increased net loss attributable to common stockholders in the calculation of basic and diluted net loss per share. This deemed dividend was recognized separately from the deemed dividend arising from the down-round adjustment to the exercise price of the 2025 Warrants described above.

 

 

The New Warrants to purchase shares of common stock were valued on the date of issuance using the Monte Carlo Simulation model with the following assumptions based on the valuation performed as of July 10, 2026:

 

Schedule of Weighted-Average Assumptions in Black Scholes Fair Value

    Assumptions  
Expected volatility     44.00 %
Risk-free interest rate     4.33 %
Stock price (pre-stock split)   $ 0.76  
Exercise price (pre-stock split)   $ 0.35  
Dividend yield     - %
Expected term (in years)     5.40  

 

Solicitation Warrants:

 

The Company engaged ThinkEquity LLC (the “Solicitation Agent”) to act as its exclusive warrant solicitation agent in connection with the transactions described above pursuant to that certain Warrant Solicitation Agent Agreement, by and between the Company and the Solicitation Agent, dated as of July 10, 2026 (the “Warrant Solicitation Agent Agreement”). Pursuant to the Warrant Solicitation Agent Agreement, the Company agreed to pay the Solicitation Agent a fee consisting of (i) a cash payment equal to 10% of the aggregate gross cash proceeds received by the Company from the Warrant Holders’ exercise of the 2025 Warrants and (ii) warrants (the “Solicitation Agent Warrants”) to purchase 24,956 shares of common stock (5% of the aggregate number of shares underlying the New Warrants issued to the Warrant Holders in connection with the transactions contemplated by the Inducement Letters).

 

The Solicitation Agent Warrants have an exercise price of $5.25 per share, will become exercisable on the date 2026 Stockholder Approval is received (or such date that 2026 Stockholder Approval is no longer required under the rules of the applicable trading market), and will expire on the fifth anniversary of such date. As of September 30, 2026, the 2026 Stockholder Approval had not been obtained and the Solicitation Agent Warrants were not exercisable. Pursuant to the Warrant Solicitation Agent Agreement, the Company also agreed to reimburse the Solicitation Agent for its reasonable legal and other expenses up to $50.

 

The following table summarizes the weighted-average assumptions used in calculating the Black Scholes fair value of the Solicitation Agent Warrants issued during the three and nine months ended September 30, 2026. The assumptions reflect the valuation of the Solicitation Agent Warrants as of July 10, 2026:

 

Schedule of Weighted-Average Assumptions in Black Scholes Fair Value

    Assumptions  
Expected volatility     46.00 %
Risk-free interest     4.25 %
Stock price on date of issuance (pre-stock split)   $ 0.76  
Exercise price (pre-stock split)   $ 0.35  
Dividend yield     — %
Expected term (in years)     5.4  

 

A summary of total warrants outstanding as of September 30, 2026 and December 31, 2025 is as follows:

 

    Shares  
Outstanding at December 31, 2024     44,445  
Issued     750,854  
Exercised     (63,083 )
Exchanged     (31,112 )
Outstanding at December 31, 2025     701,104  
Issued     633,587  
Exercised     (499,107 )*
Exchanged     —  
Expired     —  
Outstanding at September 30, 2026     835,584  

 

· Includes 13,333 HEZBAY warrants held in abeyance.

 

 

Basic and diluted net loss per common share

 

Net loss per share information is determined using the two-class method. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company’s convertible preferred stock and outstanding warrants participate in any dividends declared by the Company on common stock on a one-for-one basis and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.

 

Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period including potential dilutive common shares. For purposes of this calculation, outstanding options and warrants to purchase common stock, and shares of convertible preferred stock are considered potential dilutive common shares. The Series D Preferred Stock, Series D Warrants, New Warrants and Solicitation Agent Warrants are not convertible or exercisable until 2026 Stockholder Approval is received. Because 2026 Stockholder Approval had not been obtained as of September 30, 2026, the shares of common stock issuable upon conversion or exercise of these securities are considered contingently issuable shares and are excluded from the computation of basic and diluted net loss per share until the contingency is satisfied, and are also antidilutive. The Company has generated net loss in all periods presented, and therefore the basic and diluted net loss per share attributable to common stockholders are the same as the inclusion of the potentially dilutive securities would be anti-dilutive.

 

For the three and nine months ended September 30, 2026 and 2025, diluted weighted average common shares outstanding are equal to basic weighted average common shares. The following potentially dilutive securities outstanding had an antidilutive impact and were therefore excluded from the computation of diluted weighted-average shares outstanding:

 

    2026     2025       2026     2025  
    Three Months Ended September 30,       Nine Months Ended September 30,  
    2026     2025       2026     2025  

Options to purchase common stock

    24,963       30,481       24,963     30,481  
Convertible preferred stock upon conversion     523,048       358,931       523,048     358,931  

Warrants to purchase common stock

    835,584       757,521       835,584     757,521